Betel Quid And Areca Nut Chewing And Some Areca Nut Derived Nitrosamines

A working group of sixteen experts from seven countries re-evaluated the evidence of the carcinogenicity of betel-quid and areca-nut chewing and some areca-nut related nitrosamines. Betel-quid and areca-nut chewing are widely practised in many parts of Asia and in Asian-migrant communities elsewhere in the world. There are hundreds of millions of users worldwide. They evaluated betel quid with tobacco as carcinogenic to humans (Group 1) on the basis of sufficient evidence of an increased risk of cancer of the oral cavity, pharynx and oesophagus. The working group reviewed epidemiological studies of human cancer, mainly studies from India, Pakistan and Taiwan (China). Studies on betel quid with tobacco and areca nut with tobacco in experimental animals now also provide sufficient evidence of carcinogenicity. The working group also evaluated betel quid without tobacco as carcinogenic to humans (Group 1), on the basis of sufficient evidence of an increased risk of oral cancer. Studies on betel quid without tobacco and areca nut without tobacco in experimental animals now also provide sufficient evidence of carcinogenicity. Areca nut, a common ingredient of betel quid and many different chewing preparations, including those available commercially, has been observed to cause oral submucous fibrosis

This eighty-ninth volume of the IARC Monographs is the third and last of a series on tobacco-related agents. Volume 83 reported on the carcinogenicity of tobacco smoke and involuntary smoking (second-hand smoke or environmental tobacco smoke) (IARC 2004a). Volume 85 summarized the evidence on the carcinogenic risk of chewing betel quid with and without tobacco (IARC 2004b). That volume explored the variety of products chewed in South Asia and other parts of the word that contain areca nut in combination with other ingredients, often including tobacco. In this eighty-ninth volume, the carcinogenic risks associated with the use of smokeless tobacco, including chewing tobacco and snuff, are considered in a first monograph. The second monograph reviews some tobacco-specific nitrosamines. These agents were evaluated earlier in Volume 37 of the Monographs (IARC 1985) and information gathered since that time has been summarized and evaluated.

This comprehensive multidisciplinary book examines all aspects of cancers of the mouth and oropharynx with the aim of equipping advanced students and practitioners in the early stages of specialist training with an up-to-date guide and reference. A multinational team of authors – all experts in the field of oral oncology – provide illuminating contributions on the full range of relevant topics: epidemiology, risk factors, clinical features, staging and prognostic factors, pathology, diagnostic techniques, disease prevention, surgery, radiotherapy, and chemotherapy. Molecular biology, molecular targeted therapies for advanced cases, and future diagnostic and prognostic applications of new technologies also receive careful attention. In providing a wealth of essential information and guidance in a practical format, the book will be a superb asset for senior graduate students in dentistry and specialist trainees in head and neck oncology. It will also be of high value for the many physicians, surgeons, pathologists, dentists, and specialists involved in the prevention, diagnosis, and management of squamous cell carcinomas of the oral cavity and oropharynx.

This Scientific Publication reviews the information on cancer sites and mechanistic events for the more than 100 agents classified in Group 1 (carcinogenic to humans) by the IARC Monographs Program. This category of agents is diverse and includes chemicals and chemical mixtures; occupations; metals, dusts, and fibres; radiation; viruses and other biological agents; personal habits; and pharmaceuticals. For the Group 1 agents, there were cross-cutting questions about the relevance to humans of certain cancer sites or mechanistic pathways in animals. This publication is based on a systematic identification and comparison of the cancer sites observed in humans and those observed in experimental animals, and a compilation of mechanistic events for agents known to cause cancer in humans. Relevant information was analyzed on all the agents classified in Group 1 in Monographs up to and including Volume 109, most of which are reviewed in Volume 100A-F. A database of tumor sites seen in humans and animals was used to examine the degree of concordance by use of an anatomically based tumor classification scheme. The analysis of mechanistic aspects of the IARC Group 1 agents focused on 10 key characteristics of human carcinogens developed during the course of this work. Genotoxicity was the most prevalent mechanistic characteristic, consistent with the process of carcinogenesis necessarily involving genomic changes. The IARC concordance database represents a useful source of information for comparing animal and human data with respect to the tumors caused in different species. The results of the mechanistic analysis can provide a basis for future efforts to categorize mechanistic data for carcinogens through a systematic review process. These reviews and analyses were discussed during a two-part Workshop on Tumour Site Concordance and Mechanisms of Carcinogenesis convened by IARC. This Scientific Publication is the report of that Workshop and of subsequent work by the participants, both individually and collectively. This publication also presents a statement of consensus among the Workshop participants, which summarizes the main findings and their implications for human cancer risk assessment.

Bioactive compounds are abundant in nature, particularly in plants, which have the capacity to synthesize phenolics, flavonoids, caffeine, carotenoids, and much more. Different bioactive compounds can change or alter the life process due to their different biological activities. This book examines bioactive compounds and their sources, structures, and potential uses in various industries, including pharmaceuticals, medicine, cosmetics, and food processing.

This book tells the fascinating story of the relationship of tobacco products to cancer, from the first discoveries to the present day cancer pandemic and regulatory activities. Although there are already excellent books and monographs on this topic, both in the popular press and as government summaries, none relate the scientific story at the level of non-specialist graduate and medical students, researchers, or educated popular science readers. In this book, with a primary focus on the United States, the editors — Stephen S Hecht and Dorothy K Hatsukami — bring together 24 renowned experts on the subject of tobacco and cancer to summarize specific aspects of this critical topic in relatively non-technical terms while also incorporating some personal insights related to the story of the discovery process. This highly authoritative book is also expected to be an excellent teaching tool and basis for a course for graduate and medical students on this important topic.